Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 191

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial

Open access
Adam, René, Piedvache, Céline, Chiche, Laurence, Adam, Jean Philippe, Salamé, Ephrem, Bucur, Petru, Cherqui, Daniel, Scatton, Olivier, Granger, Victoire, Ducreux, Michel, Cillo, Umberto, Cauchy, François, Mabrut, Jean-Yves, Verslype, Chris, Coubeau, Laurent, Hardwigsen, Jean, Boleslawski, Emmanuel, Muscari, Fabrice, Jeddou, Heithem, Pezet, Denis, Heyd, Bruno, Lucidi, Valerio, Geboes, Karen, Lerut, Jan, Majno, Pietro, Grimaldi, Lamiae, Levi, Francis, Lewin, Maïté, Gelli, Maximiliano, Adam, René, Piedvache, Céline, Chiche, Laurence, Adam, Jean Philippe, Salamé, Ephrem, Bucur, Petru, Cherqui, Daniel, Scatton, Olivier, Granger, Victoire, Ducreux, Michel, Cillo, Umberto, Cauchy, François, Mabrut, Jean-Yves, Cauchy, François, Mabrut, Jean-Yves, Verslype, Chris, Coubeau, Laurent, Hardwigsen, Jean, Boleslawski, Emmanuel, Muscari, Fabrice, Jeddou, Heithem, Pezet, Denis, Heyd, Bruno, Lucidi, Valerio, Geboes, Karen, Lerut, Jan, Majno, Pietro, Grimaldi, Lamiae, Levi, Francis, Lewin, Maïté, Gelli, Maximiliano, Soubrane, Olivier, Lesurtel, Mickael, Bachet, Jean Baptsite, Lesourd, Samuel, Jary, Marine, Bouattour, Mohamed, Lonardi, Sara, Hebbar, Mohamed, Boudjema, Karim, Smith, Denis, Chirica, Mircea, Lecomte, Thierry, Borg, Chirstophe, Guimbaud, Rosine, Taieb, Julien, Burra, Patrizia, Rougier, Philippe, Figueras, Joan · 2024 · The Lancet

Abstract

BACKGROUND Despite the increasing efficacy of chemotherapy, permanently unresectable colorectal liver metastases are associated with poor long-term survival. We aimed to assess whether liver transplantation plus chemotherapy could improve overall survival. METHODS TransMet was a multicentre, open-label, prospective, randomised controlled trial done in 20 tertiary centres in Europe. Patients aged 18-65 years, with Eastern Cooperative Oncology Group performance score 0-1, permanently unresectable colorectal liver metastases from resected BRAF-non-mutated colorectal cancer responsive to systemic chemotherapy (≥3 months, ≤3 lines), and no extrahepatic disease, were eligible for enrolment. Patients were randomised (1:1) to liver transplantation plus chemotherapy or chemotherapy alone, using block randomisation. The liver transplantation plus chemotherapy group underwent liver transplantation for 2 months or less after the last chemotherapy cycle. At randomisation, the liver transplantation plus chemotherapy group received a median of 21·0 chemotherapy cycles (IQR 18·0-29·0) versus 17·0 cycles (12·0-24·0) in the chemotherapy alone group, in up to three lines of chemotherapy. During first-line chemotherapy, 64 (68%) of 94 patients had received doublet chemotherapy and 30 (32%) of 94 patients had received triplet regimens; 76 (80%) of 94 patients had targeted therapy. Transplanted patients received tailored immunosuppression (methylprednisolone 10 mg/kg intravenously on day 0; tacrolimus 0·1 mg/kg via gastric tube on day 0, 6-10 ng/mL days 1-14; mycophenolate mofetil 10 mg/kg intravenously day 0 to <2 months and switch to everolimus 5-8 ng/mL), and postoperative chemotherapy, and the chemotherapy group had continued chemotherapy. The primary endpoint was 5-year overall survival analysed in the intention to treat and per-protocol population. Safety events were assessed in the as-treated population. The study is registered with ClinicalTrials.gov (NCT02597348), and accrual is complete. FINDINGS Between Feb 18, 2016, and July 5, 2021, 94 patients were randomly assigned and included in the intention-to-treat population, with 47 in the liver transplantation plus chemotherapy group and 47 in the chemotherapy alone group. 11 patients in the liver transplantation plus chemotherapy group and nine patients in the chemotherapy alone group did not receive the assigned treatment; 36 patients and 38 patients in each group, respectively, were included in the per-protocol analysis. Patients had a median age of 54·0 years (IQR 47·0-59·0), and 55 (59%) of 94 patients were male and 39 (41%) were female. Median follow-up was 59·3 months (IQR 42·4-60·2). In the intention-to-treat population, 5-year overall survival was 56·6% (95% CI 43·2-74·1) for liver transplantation plus chemotherapy and 12·6% (5·2-30·1) for chemotherapy alone (HR 0·37 [95% CI 0·21-0·65]; p=0·0003) and 73·3% (95% CI 59·6-90·0) and 9·3% (3·2-26·8), respectively, for the per-protocol population. Serious adverse events occurred in 32 (80%) of 40 patients who underwent liver transplantation (from either group), and 69 serious adverse events were observed in 45 (83%) of 54 patients treated with chemotherapy alone. Three patients in the liver transplantation plus chemotherapy group were retransplanted, one of whom died postoperatively of multi-organ failure. INTERPRETATION In selected patients with permanently unresectable colorectal liver metastases, liver transplantation plus chemotherapy with organ allocation priority significantly improved survival versus chemotherapy alone. These results support the validation of liver transplantation as a new standard option for patients with permanently unresectable liver-only metastases. FUNDING French National Cancer Institute and Assistance Publique-Hôpitaux de Paris.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)01595-2

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 191

Metadata

Authors
Adam, R., Piedvache, C., Chiche, L., Adam, J. P., Salamé, E., Bucur, P., Cherqui, D., Scatton, O., Granger, V., Ducreux, M., Cillo, U., Cauchy, F., Mabrut, J.-Y., Verslype, C., Coubeau, L., Hardwigsen, J., Boleslawski, E., Muscari, F., Jeddou, H., Pezet, D., Heyd, B., Lucidi, V., Geboes, K., Lerut, J., Majno, P., Grimaldi, L., Levi, F., Lewin, M., Gelli, M., Adam, R., Piedvache, C., Chiche, L., Adam, J. P., Salamé, E., Bucur, P., Cherqui, D., Scatton, O., Granger, V., Ducreux, M., Cillo, U., Cauchy, F., Mabrut, J.-Y., Cauchy, F., Mabrut, J.-Y., Verslype, C., Coubeau, L., Hardwigsen, J., Boleslawski, E., Muscari, F., Jeddou, H., Pezet, D., Heyd, B., Lucidi, V., Geboes, K., Lerut, J., Majno, P., Grimaldi, L., Levi, F., Lewin, M., Gelli, M., Soubrane, O., Lesurtel, M., Bachet, J. B., Lesourd, S., Jary, M., Bouattour, M., Lonardi, S., Hebbar, M., Boudjema, K., Smith, D., Chirica, M., Lecomte, T., Borg, C., Guimbaud, R., Taieb, J., Burra, P., Rougier, P., & Figueras, J.
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-09
Volume
404
Issue
10458
Pages
1107-1118
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4402623972
Cited by
191
References
2
FWCI
29.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01595-2
The paper
Adam, R., Piedvache, C., Chiche, L., Adam, J. P., Salamé, E., Bucur, P., Cherqui, D., Scatton, O., Granger, V., Ducreux, M., Cillo, U., Cauchy, F., Mabrut, J.-Y., Verslype, C., Coubeau, L., Hardwigsen, J., Boleslawski, E., Muscari, F., Jeddou, H., . . . Figueras, J. (2024). Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)01595-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.